文献速递疼痛医学神经外科与老年麻醉

Pexidartinib通过影响小鼠小胶质细胞和神经炎症缓解神经病理性疼痛

The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice.
PubMed 文献 · Anesth Analg · 2024-10-30

该研究在小鼠慢性压迫性损伤(CCI)模型中,每日口服PLX-3397或溶媒共21天,造模后再给药28天,发现PLX-3397显著改善疼痛相关行为,并减少小胶质细胞及神经炎症标志物,提示其作为镇痛药的潜力。

要点

  • PLX-3397在CCI小鼠中持续改善疼痛相关行为。
  • PET神经影像和免疫荧光显示PLX-3397减少小胶质细胞。
  • PLX-3397降低iNOS等神经炎症相关蛋白表达。

核心结论

  • PLX-3397通过减少小胶质细胞和神经炎症减轻小鼠神经病理性疼痛。
  • 研究为测试PLX-3397作为镇痛药提供了新的概念验证数据。

研究设计与样本

  • 使用CCI小鼠模型,PLX-3397或溶媒每日口服21天,造模后再给药28天。
  • 采用PET神经影像和免疫荧光/免疫组化检测小胶质细胞及神经炎症标志物。

临床怎么用

  • PLX-3397为FDA已批准抗癌药及CSF-1R抑制剂,具有小胶质细胞耗竭特性。
  • 该研究为临床前证据,支持进一步评估PLX-3397作为镇痛药的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise of pain amelioration can be achieved using the small-molecule pexidartinib (PLX-3397), a previously food and drug administration (FDA)-approved cancer medicine and a colony-stimulating factor-1 receptor (CSF-1R) inhibitor that display microglia-depleting properties. METHOD: We used the previously reported chronic constriction injury (CCI) mouse model, in which PLX-3397 or vehicle was orally administrated to mice daily for 21 days, then applied to the CCI model, followed by PLX-3397 or vehicle administration for an additional 28 days. Additionally, we examined microglia-related neuroinflammation markers using positron emission tomography (PET) neuroimaging and immunofluorescence (IF). RESULTS: We showed that PLX-3397 significantly ameliorated pain-related behavioral changes throughout the entire experimental period after CCI (vehicle versus PLX-3397 at day 14, effect size: 2.57, P = .002). Microglia changes were first analyzed by live-animal PET neuroimaging, revealing PLX-3397-associated reduction of microglia by probing receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a protein primarily expressed in microglia, which were further corroborated by postmortem immunohistochemistry (IHC) analysis using antibodies for microglia, including ionized Ca 2+ binding adaptor molecule 1 (Iba-1) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 3.6, P = .011) and RIPK1 (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size 2.9, P = .023. The expression of both markers decreased in the PLX-3397 group. Furthermore, we found that PLX-3397 led to significant reductions in various proteins, including inducible nitric oxide synthase (iNOS) (somatosensory cortex, hindlimb area; vehicle versus PLX-3397, effect size: 2.3, P = .048), involved in neuroinflammation through IHC. CONCLUSIONS: Collectively, our study showed PLX-3397-related efficacy in ameliorating pain linked to the reduction of microglia and neuroinflammation in mice. Furthermore, our research provided new proof-of-concept data supporting the promise of testing PLX-3397 as an analgesic.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Yang L, Gomm A, Bai P, et al. The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice. Anesth Analg. 2024. PMID: 39475839. doi:10.1213/ANE.0000000000007239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。